SecBot SecBot

CERS

CERUS CORP
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001020214 Healthcare & Medical Devices
$2.34 +0.01 (+0.43%)
Oct 26 4:00 PM ET · prev $2.33
Market cap
$465.5M
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$5.00
+114% · range $4.00–6.50
Next earnings
Nov 2
in 7 days · EPS est. −$0.01
1 year
+51.9%
from $1.54 · Oct 27
30 days
−4.5%
from $2.45
52-week range
$1.40–3.28
−29% from high · low Oct 30
Avg volume 20D
1.71M
shares / day
Short interest
17.58M
≈8.7% of shares · −2.3%
Days to cover
8.0
at average volume
Insider net
-$3.0M
0 buyers · 6 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 3 reports · latest
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 2, 2026
Strongest BULLISH Cerus Corporation received a $33.2 million contract modification from the Department of Health and Human…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S Mar 5 to Mar 12 4 days of insider sells: $2.1M by 5 insiders, avg $1.76
  • S Jun 9 1 insider sell $53.2K at $2.60
  • S Jun 30 4 insiders sell $595.3K at $2.94
  • S Jul 16 1 insider sell $52.7K at $3.16
  • R Jul 21 Cerus Corporation received a $33.2 million contract modification fro…
  • E Jul 21 Gov. contract: $33M govt contract mod: CERUS CORPORATION
  • S Aug 17 1 insider sell $89.5K at $2.98
  • A Aug 20 Freedom Broker initiates

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $3.0M.

  • InstitutionsMIXED

    Q2 2026: 23 added (0 new), 16 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.010 → −$0.015 over 90 days.

  • Short sellersSTEADY

    Short interest −2.3% to 17.58M shares. 8.0 days to cover, ≈8.7% of shares.

  • TrendDOWNTREND

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BAKER BROS. ADVISORS LPTRIM6,395,431$18.7M
D. E. Shaw & Co., Inc.ADD5,485,983$16.0M
WASATCH ADVISORS LPTRIM3,383,899$9.9M
MACKENZIE FINANCIAL CORPDOUBLED3,002,694$8.8M
VANGUARD PORTFOLIO MANAGEMENT LLCADD2,768,990$8.1M
AMERIPRISE FINANCIAL INCDOUBLED1,159,506$3.4M
MORGAN STANLEYADD1,118,262$3.3M
PANAGORA ASSET MANAGEMENT INCDOUBLED1,093,822$3.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy3Buy6Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +114%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 20, 2026Freedom Broker
INITIATE
INITIATEBuy
May 1, 2026BTIG
UPGRADE
UPGRADEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$3.0M
sold · 6 insiders
DateInsiderTypeValue
Aug 17, 2026
Jensen Chrystal
Chief Legal Officer
SELL$89.5K
Jul 16, 2026
Jayaraman Vivek K
Chief Executive Officer
SELL$52.7K
Jul 1, 2026
Jayaraman Vivek K
Chief Operating Officer
AWARD554,529 sh
Jul 1, 2026
Jayaraman Vivek K
Chief Operating Officer
AWARD369,686 sh
Jun 30, 2026
Jensen Chrystal
Chief Legal Officer
SELL$71.6K
Jun 30, 2026
Jensen Chrystal
Chief Legal Officer
AWARD55,000 sh
Jun 30, 2026
Greenman William Mariner
President and CEO
AWARD192,500 sh
Jun 30, 2026
Greenman William Mariner
President and CEO
SELL$299.9K

Earnings setup

Estimates
Nov 2
reports in 7 days
−$0.01
EPS estimate, this quarter
−50%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.01-$0.02–-$0.01-50.0%$61.1M
Next Q🔒 Fresh data, subscribers only
Current FY-$0.04-$0.05–-$0.04-50.0%$249.1M
Next FY-$0.01-$0.01–$0.00—$271.5M

Short side

FINRA· Sep 30, 2026
17,580,423
shares short
-2.3%
vs prior settlement
8.0
days to cover
≈8.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 31, 2026 Short interest report
Short Interest: CERS up 2% to 17.7M shares
Settlement 2026-08-31 | Days to cover: 10.02 | ≈8.79% of shares outstanding (est.)
Aug 17, 2026 Insider
Jensen Chrystal sold 30,000 shares
Chief Legal Officer @ $2.98 ($89.5K)
Jul 21, 2026 SEC
Cerus Corporation received a $33.2 million contract modification from the Department of Health and Human Services…
GOVT-CONTRACT — Impact 7/10
Jul 16, 2026 Insider
Jayaraman Vivek K sold 16,666 shares
Chief Executive Officer @ $3.16 ($52.7K)
Jul 2, 2026 SEC
Insider cluster at Cerus Corp shows open-market sales by CEO, CFO, and COO totaling $524K, which is only ~0.09% of…
CLUSTER — Impact 2/10
Jul 2, 2026 SEC
Two C-suite insiders at Cerus Corp (CERS) sold a combined $224K in open-market shares on June 30, 2026, representing…
CLUSTER — Impact 2/10
Jul 1, 2026 Insider
Jayaraman Vivek K was granted 554,529 shares
Chief Operating Officer
Jun 30, 2026 Inst.
BAKER BROS. ADVISORS LP — TRIM
6,395,431 shares ($18.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
CERS Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Sep 22, 2026
Clinical Trial
Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Phase 3 · COMPLETED
Aug 31, 2026
Short interest
Short Interest: CERS up 2% to 17.7M shares
Settlement 2026-08-31 | Days to cover: 10.02 | ≈8.79% of shares outstanding (est.)
Aug 4, 2026
Clinical Trial
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
Phase 2 · COMPLETED
Jul 30, 2026
Earnings date
CERS Q2 2026 Earnings Scheduled — 2026-07-30
Jul 21, 2026
Gov. contract
$33M govt contract mod: CERUS CORPORATION
Agency: Department of Health and Human Services. Mod P00003: SUPPLEMENTAL FUNDING TO THE BASE PERIOD (CLIN 0001, CLIN 0002 & CLIN 0003); EXERCISE…

SecBot reports

9 filings · 2 bullish · 1 bearish · 6 neutral
All CERS filing & press-release reports (9)